Ensysce Biosciences, INC. (ENSCW) — SEC Filings

Overview

Ensysce Biosciences, INC. (ENSCW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Dec 16, 2025: Ensysce Biosciences, Inc. filed a Definitive Additional Materials (DEFA14A) on December 16, 2025. This filing relates to proxy materials and does not require a fee. The company, previously known as Leisure Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 2 bearish, 27 neutral, 3 mixed. The dominant filing sentiment for Ensysce Biosciences, INC. is neutral.

Filing Type Overview

Ensysce Biosciences, INC. (ENSCW) has filed 2 DEFA14A, 1 DEF 14A, 16 8-K, 5 10-Q, 2 10-K, 3 SC 13G, 1 S-1/A, 1 SC 13G/A, 1 S-1 with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (32)

• Ensysce Biosciences Files Proxy Materials — DEFA14A · Dec 16, 2025 Risk: low
  Ensysce Biosciences, Inc. filed a Definitive Additional Materials (DEFA14A) on December 16, 2025. This filing relates to proxy materials and does not require a
• Ensysce Seeks Shareholder Nod for $3.6M Capital Raise, Incentive Plan Boost — DEF 14A · Dec 2, 2025 Risk: medium
  Ensysce Biosciences, Inc. (ENSCW) is seeking stockholder approval for several key proposals at its Annual Meeting on December 23, 2025. The company recently com
• 8-K Filing — 8-K · Nov 17, 2025
• Ensysce's Net Loss Widens 67% Amid Soaring R&D Costs — 10-Q · Nov 14, 2025 Risk: high
  Ensysce Biosciences, Inc. (ENSCW) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $7,408,218, compared to a n
• Ensysce Narrows Losses Amid R&D Surge, Grant Influx — 10-Q · Aug 13, 2025 Risk: high
  Ensysce Biosciences, Inc. reported a net loss of $3,679,090 for the six months ended June 30, 2025, a significant improvement from the $5,084,356 net loss in th
• Ensysce Biosciences Changes Auditors to BDO USA, LLP — 8-K · Jun 5, 2025 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on June 5, 2025, reporting a change in its certifying accountant. The company previously engaged WithumSmith+Brown, PC, b
• Ensysce Biosciences Files 8-K on Operations — 8-K · May 13, 2025 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhi
• Ensysce Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 24, 2025 Risk: medium
  Ensysce Biosciences, Inc. announced on April 23, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• Ensysce Biosciences Files 8-K — 8-K · Apr 1, 2025 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on April 1, 2025, reporting other events and financial statements. The company, formerly known as Leisure Acquisition Cor
• Ensysce Biosciences Enters Material Definitive Agreement — 8-K · Mar 31, 2025 Risk: medium
  On March 30, 2025, Ensysce Biosciences, Inc. entered into a Material Definitive Agreement related to unregistered sales of equity securities. The company, forme
• Ensysce Biosciences Files 2024 10-K — 10-K · Mar 10, 2025 Risk: medium
  Ensysce Biosciences, Inc. filed its 2024 10-K on March 10, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Leisure Acquisitio
• Ensysce Biosciences Enters Material Definitive Agreement — 8-K · Feb 4, 2025 Risk: medium
  Ensysce Biosciences, Inc. announced on February 4, 2025, that it entered into a material definitive agreement. The filing does not specify the other party or th
• Ensysce Biosciences Files 8-K for Bylaw Amendments — 8-K · Dec 3, 2024 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on December 3, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The filing
• Ensysce Biosciences Files 8-K on Security Holder Vote — 8-K · Nov 21, 2024 Risk: medium
  Ensysce Biosciences, Inc. filed an 8-K on November 21, 2024, to report on the submission of matters to a vote of its security holders. The filing indicates that
• Ensysce Biosciences Files Proxy Materials — DEFA14A · Nov 19, 2024 Risk: low
  Ensysce Biosciences, Inc. filed a Definitive Additional Materials (DEFA14A) on November 19, 2024. This filing relates to the company's proxy statement and does
• SC 13G Filing — SC 13G · Nov 14, 2024
• Ensysce Biosciences Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Ensysce Biosciences, Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, formerly Leisure Acquisition Corp., is focused on phar
• SC 13G Filing — SC 13G · Nov 6, 2024
• SC 13G Filing — SC 13G · Oct 29, 2024
• Ensysce Biosciences Files 8-K for Bylaw Amendments & Financials — 8-K · Oct 18, 2024 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on October 18, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The compan
• Ensysce Biosciences Files 8-K: Material Agreement, Equity Sales — 8-K · Aug 30, 2024 Risk: medium
  Ensysce Biosciences, Inc. announced on August 29, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• Ensysce Biosciences Faces Nasdaq Delisting Warning — 8-K · Aug 23, 2024 Risk: medium
  Ensysce Biosciences, Inc. announced on August 23, 2024, that it received a notice from The Nasdaq Stock Market on August 20, 2024, indicating non-compliance wit
• Ensysce Biosciences Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Ensysce Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Leisure Acquisition Corp., is focused on pharmaceutical prep
• Ensysce Biosciences Files 8-K — 8-K · May 28, 2024 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on May 28, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Leisure
• Ensysce Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  Ensysce Biosciences, Inc. (ENSCW) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Ensysce Biosciences, Inc. filed a 10-Q report for the period end
• Ensysce Biosciences Sells Subsidiary for $10M Cash & Equity — 8-K · May 9, 2024 Risk: medium
  Ensysce Biosciences, Inc. announced on May 9, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Ensysce Health, Inc., t
• Ensysce Biosciences Faces Delisting Concerns — 8-K · Mar 29, 2024 Risk: high
  Ensysce Biosciences, Inc. filed an 8-K on March 29, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event rep
• Ensysce Biosciences Files S-1/A Amendment — S-1/A · Mar 26, 2024 Risk:
  Ensysce Biosciences, Inc. (ENSCW) filed a Amended IPO Registration (S-1/A) with the SEC on March 26, 2024. Ensysce Biosciences, Inc. filed an S-1/A amendment on
• Ensysce Biosciences Files 2023 10-K Report — 10-K · Mar 15, 2024 Risk: medium
  Ensysce Biosciences, Inc. (ENSCW) filed a Annual Report (10-K) with the SEC on March 15, 2024. Ensysce Biosciences, Inc. filed its 10-K for the fiscal year endi
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Ensysce Biosciences Reports Equity Sales & Material Agreement — 8-K · Feb 14, 2024 Risk: medium
  On February 12, 2024, Ensysce Biosciences, Inc. entered into a material definitive agreement and completed unregistered sales of equity securities. This 8-K fil
• Ensysce Biosciences Files S-1 for Potential Public Offering — S-1 · Jan 17, 2024 Risk:
  Ensysce Biosciences, Inc. (ENSCW) filed a IPO Registration (S-1) with the SEC on January 17, 2024. Ensysce Biosciences, Inc. filed an S-1 registration statement

Risk Profile

Risk Assessment: Of ENSCW's 25 recent filings, 3 were flagged as high-risk, 14 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Ensysce Biosciences, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $3,184,314
• Net Income: -$7,408,218
• EPS: -$3.42
• Cash Position: $1,673,218
• Total Assets: $3,179,464

Key Executives

• Dr. Lynn Kirkpatrick

Industry Context

Ensysce Biosciences operates in the biotechnology sector, focusing on the development of novel drug delivery platforms. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success hinges on clinical trial outcomes and the ability to secure funding for ongoing research and development.

Top Tags

financials (5) · corporate-governance (4) · material-agreement (4) · Ensysce Biosciences (4) · SEC Filing (4) · Biotechnology (3) · equity-sale (3) · pharmaceuticals (3) · 10-Q (3) · proxy-filing (2)

Key Numbers

• Gross proceeds from Registered Direct Offering: $1.7M — Capital raised from the sale of Preferred Stock and Common Stock
• Shares of Series B Preferred Stock: 1,513 — Issued in the Registered Direct Offering
• Shares of Common Stock: 665,922 — Issuable upon conversion of Preferred Stock in Registered Direct Offering
• Unregistered shares of Preferred Stock: 2,487 — Issued in the concurrent Private Placement
• Warrants to purchase Common Stock: 880,000 — Issued in the Private Placement with an exercise price of $2.50
• Warrant exercise price: $2.50 — Per share exercise price for warrants issued in Private Placement
• Estimated net proceeds from Offerings: $3.6M — Intended for general corporate purposes, TAAP/MPAR programs, and working capital
• Total shares for 2021 Omnibus Incentive Plan: 721,457 — Proposed increase from 121,457 shares, representing a 600,000 share increase
• Exchange Cap: 19.99% — Maximum percentage of outstanding Common Stock that can be issued without stockholder approval under Nasdaq rules
• Net loss for nine months ended Sept 30, 2025: $7,408,218 — Increased by 67.5% from $4,422,587 in 2024
• Cash and cash equivalents as of Sept 30, 2025: $1,673,218 — Decreased from $3,502,077 at Dec 31, 2024
• Total operating expenses for nine months ended Sept 30, 2025: $10,643,435 — Increased by 50.7% from $7,060,030 in 2024
• Research and development expenses for nine months ended Sept 30, 2025: $6,763,866 — More than doubled from $3,416,807 in 2024
• Federal grants for nine months ended Sept 30, 2025: $3,184,314 — Decreased by 18.5% from $3,906,372 in 2024
• Net cash provided by financing activities for nine months ended Sept 30, 2025: $4,575,243 — Significantly lower than $9,768,598 in 2024

Related Companies

ENSY · ENSC · ENS

Frequently Asked Questions